Summary
Optical coherence tomography (OCT) is a non-invasive, transpupillary imaging technology that allows detailed analysis of the retinal structures. In a recent article, Gualino et al. reported that OCT revealed a foveolar cystoid space with focal disruption of the photoreceptors line that explains the irreversible loss of central vision in tamoxifen retinopathy. In addition to providing a better understanding of the pathogenesis of tamoxifen retinopathy, OCT screening is advisable in patients treated with tamoxifen over long periods in order to detect and prevent drug-induced retinal damage.
References
Gualino V, Cohen S, Delyfer M, Sahel J, Gaudric A: Optical coherence tomography findings in tamoxifen retinopathy Am J Ophthalmol140:757–758, 2005
Heier J, Dragoo R, Enzenauer R, Waterhouse W: Screening for ocular toxicity in asymptomatic patients treated tamoxifenAm J Ophthalmol117: 112–113, 1994
Kaiser Kupfer M, Kupfer C, Rodrigues M: Tamoxifen retinopathy. A clinicopathologic reportOphthalmology88: 89–93, 1981
Pierre-Kahn V, Tadayoni R, Haouchine B, Massin P, Gaudric A: Comparison of optical coherence tomography models OCT1 and Stratus OCT for macular retinal thickness measurement Br J Ophthalmol89: 1581–1585, 2005
Mäenpää H, Mannerström M, Toimela T, Saminen L, Saransaari P, Tahti H: Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells Pharmacol Toxicol 91: 116–122, 2002
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s10549-006-9283-z
Rights and permissions
About this article
Cite this article
Martine, MF., Joël, G. & Maddalena, QE.M. Optical coherence tomography in tamoxifen retinopathy. Breast Cancer Res Treat 99, 117–118 (2006). https://doi.org/10.1007/s10549-006-9187-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9187-y